VALOR – Valsartan/HCTZ Combination Therapy in Patients With Moderate to Severe Systolic Hypertension
The results of the Valsartan/HCTZ Combination Therapy in Patients With Moderate to Severe Systolic Hypertension (VALOR) study [1] show that valsartan 160 mg once daily is safe and effective in older ...
Concomitant therapy with the following medications was prohibited: other ARBs, angiotensin-converting enzyme (ACE) inhibitors, β-adrenergic antagonists, calcium-channel blockers, any other ...
The main purpose of the two open, non-comparative PMS studies reported here was to extend the knowledge base of the efficacy and tolerability of once-daily valsartan (trial 1) and the fixed ...
In this context, many preclinical and small clinical studies with surrogate end points suggested that several antihypertensive drug categories, especially ARBs, angiotensin-converting enzyme ...
Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/12.5 mg, 90-count bottles, lot. Nos. 20x006 and 21x006, expiration 11/2018. Amlodipine, Valsartan, and Hydrochlorothiazide Tablets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results